RxSight Stock

rxsight.comHealthcare / Medical DevicesFunding to Date: $179.84MM

RxSight is the developer of the first and only adjustable intraocular lens (IOL) that is customized after cataract surgery, enabling doctors and patients to predictably optimize vision after cataract surgery through an office based IOL enhancement.

Register To Buy and Sell Private Company Shares

For more details on financing and valuation of private companies similar to RxSight before its IPO, register or login today.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value

Powered by Forge Data

Access valuation and stock price for companies like RxSight before its IPO.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Access Stock Price

Animation displayed is not current and securities are shown for illustrative purposes only.

RxSight stock FAQs

plusminus

Can you buy RxSight stock?

You can no longer buy RxSight stock on a secondary marketplace as this company is no longer private. If you are interested in buying stock of other private companies, learn more about how to invest in the private market or register today to get started.
plusminus

How to buy RxSight stock?

To invest in a private company like RxSight through Forge, you must first qualify as an accredited investor. (Learn more about the accreditation process.)
  1. Create a free account to access Forge’s marketplace.
  2. Express your interest in specific investments. Within Forge Markets, you will find detailed pricing and financing information for thousands of private companies.
  3. Throughout this process, a dedicated Forge Private Market Specialist will be available to address any questions you may have and to guide you seamlessly through each step of the transaction.
plusminus

Can you sell RxSight stock?

You can no longer sell stock of RxSight on Forge as this company is no longer private. However, if you own stock of a private company, Forge may help you sell it in a way that works for you and the company. Learn more or register with us today to get started.
plusminus

How to sell RxSight stock?

If you hold private company shares of RxSight - whether as an employee or an early investor - Forge can help you sell them.
  1. Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have.
  2. Indicate your interest to sell your RxSight stock on our platform.
  3. Work with your dedicated Private Market Specialist who’ll help guide you through every step of the transaction.
plusminus

Is RxSight a public company?

No, RxSight is a privately held company and is currently not publicly traded on any stock markets including NYSE or NASDAQ.
plusminus

What is RxSight’s stock price?

The stock price of RxSight is $46.36 as of 1/18/24.
plusminus

What is RxSight’s stock ticker symbol?

The ticker symbol of RxSight is RXST.
plusminus

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Team

Management Team

Shelley Thunen
Chief Financial Officer
Robert Grubbs
Co-Founder
Ronald Kurtz MD
Chief Executive Officer, President & Board Member
Christian Sandstedt Ph.D
Vice President, Optics Research & Development
Matthew Haller Ph.D
Chief Technology Officer
Eric Weinberg
Chief Commercial Officer

Board Members

Christopher Cox JD
Werner Wolfen
Javier Perez-Sala
Bruce Robertson Ph.D
H.I.G. BioHealth Partners
J. Corley
Ronald Kurtz MD
Juliet Bakker
Longitude Capital
Jan Bonel
Daniel Schwartz
William Link Ph.D
Flying L Partners
Joseph Devivo
James Adler
Venture investors are providing $69 million to Calhoun Vision Inc. and betting that its technology will make it stand out in a crowded market for artificial lenses used in cataract patients.
Updated on: Jul 26, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.